Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer

H Borghaei, S Gettinger, EE Vokes… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Immunotherapy has revolutionized the treatment of advanced non–small-cell
lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057) …
被引用次数：443 相关文章

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung …

H Borghaei, S Gettinger, EE Vokes… - Journal of Clinical …, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> Immunotherapy has
revolutionized the treatment of advanced non–small-cell lung cancer (NSCLC). In two phase …

Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer

H Borghaei, S Gettinger… - Journal of …, 2021 - utsouthwestern.elsevierpure.com
PURPOSE Immunotherapy has revolutionized the treatment of advanced non-small-cell
lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057) …

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung …

H Borghaei, S Gettinger, EE Vokes… - Journal of Clinical …, 2021 - europepmc.org
Purpose Immunotherapy has revolutionized the treatment of advanced non-small-cell lung
cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab …
[HTML] nih.gov

[HTML][HTML] Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell …

H Borghaei, S Gettinger, EE Vokes… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Immunotherapy has revolutionized the treatment of advanced non–small-cell
lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057) …

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung …

H Borghaei, S Gettinger, EE Vokes… - Journal of clinical …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose Immunotherapy has revolutionized the treatment of advanced non-small-cell lung
cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab …